Compare HELP & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HELP | BCX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.2M | 930.9M |
| IPO Year | 2020 | N/A |
| Metric | HELP | BCX |
|---|---|---|
| Price | $10.50 | $11.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $41.54 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 150.5K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $9.70 |
| 52 Week High | $15.15 | $13.86 |
| Indicator | HELP | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 42.28 |
| Support Level | $9.97 | $11.39 |
| Resistance Level | $11.74 | $11.90 |
| Average True Range (ATR) | 0.83 | 0.18 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 42.61 | 18.03 |
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies, or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.